- ￥2980
- Sino Biological
- 北京
- 10881-HCCH
- 2025年08月12日
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
在-20℃ to -80℃
- 保质期：
12个月
- 英文名：
Recombinant Human Ephrin-B2 / EFNB2 Protein
- 库存：
99
- 供应商：
北京义翘神州科技股份有限公司
- 规格：
100 µg
蛋白名称：Ephrin B2蛋白, Ephrin B2 protein
蛋白构建：A DNA sequence encoding the human EFNB2 (NP_004084.1) (Met1-Ala229) was expressed with six amino acids (ENLYFQ) at the C-terminus was expressed and purified.
表达宿主：HEK293 Cells
蛋白纯度：> 95 % as determined by SDS-PAGE
蛋白活性：1.Measured by its binding ability in a functional ELISA. 2.Immobilized human EFNB2 (Cat:10881-HCCH) at 10μg/mL (100μL/well) can bind biotinylate human EphB4-Fc (Cat:10235-H02H), the EC50 of biotinylate human EphB4-Fc is 5-60 ng/mL.
蛋白内毒素：< 1.0 EU per μg of the protein as determined by the LAL method
预测N端：Ile 28
蛋白分子量：The recombinant human EFNB2 consists of 209 amino acids and predicts a molecular mass of 23.1 KDa. It migrates as an approximately 32-36 KDa band in SDS-PAGE under reducing conditions.
蛋白NP号：NP_004084.1
蛋白氨基酸序列：Met1-Ala229
蛋白标签：C-cleavage
蛋白保存条件：Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Using the scan‐x Web Site to Predict Protein Post‐Translational Modifications
spectrometry data is providing evidence that almost every protein in the cell undergoes some form of post?translational modification. We describe a protocol to use the scan?x Web site to view predicted acetylation sites in the human proteome and predicted
Searching for Non‐B DNA‐Forming Motifs Using nBMST (Non‐B DNA Motif Search Tool)
conformations, genomic rearrangements, and human disease. J. Biol. Chem. 279:47411‐47414. Bacolla, A. and Wells, R.D. 2009. Non‐B DNA conformations as determinants of mutagenesis
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B
of bleeding episodes and reduce long term complications (3). Treatment of hemophilia B primarily relies on intravenous injections of FIX protein purified from pooled human plasma, or very recently, on newly developed recombinant FIX. Treatment is applied
技术资料暂无技术资料 索取技术资料
